Table 2.

Distribution of the outcomes among all singleton pregnancies resulting in livebirth in Sweden, by proton pump inhibitor (PPI) exposure

	Total		PPI users		PPI non-users
	N	%	N	%	N	%
Total	1,089,515	100.00%	14,787	1.40%	1,074,728	98.60%
Pre-eclampsia
Yes	35,791	3.30%	723	4.90%	35,068	3.30%
No	1,053,724	96.70%	14,064	95.10%	1,039,660	96.70%
Gestational diabetes
Yes	15,958	1.50%	475	3.20%	15,483	1.40%
No	1,073,557	98.50%	14,312	96.80%	1,059,245	98.60%
Preterm birth
Yes	50,765	4.70%	966	6.50%	49,799	4.60%
No	1,038,750	95.30%	13,821	93.50%	1,024,929	95.40%
Low Apgar score
Yes	12,834	1.20%	239	1.60%	12,595	1.20%
No	1,076,681	98.80%	14,548	98.40%	1,062,133	98.80%
Birthweight for gestational age
Small	24,690	2.30%	472	3.20%	24,218	2.30%
Average	1,027,099	94.20%	13,737	92.90%	1,013,362	94.30%
Large	37,726	3.50%	578	3.90%	37,148	3.50%

^*Comorbidities defined as at least one diagnosis of hypertension, diabetes mellitus, and hypo- or hyperthyroidism

^**Other drugs defined as at least one prescription of non-steroid anti-inflammatory drugs (NSAIDs), low-dose aspirin, or antibiotics 3 months before or during gestation